Perseus Proteomics: Announcements of individual stocks regarding the large exercise, completion of exercise, and monthly exercise status of the 28th subscription rights (with exercise price adjustment clause) through third-party allocation.
Perseus Proteomics: Announcements of individual stocks regarding monthly exercise status of 28th subscription rights (with exercise price adjustment clause) by third party allotment.
Perseus Proteomics: Announcements of individual stocks: Notice regarding the completion of Phase I clinical trial for genuine polycythemia vera (PV) - PPMX-T003
Perseus Proteomics: Announcements of individual stocks: PPMX-T003: Announcement of the end of Phase I trial for polycythemia vera (PV).
Perseus Proteomics: Announcements of individual stocks: Publication of a paper on ANKL therapy co-authored by Osaka University and Perseus Proteomics
Perseus Proteomics: Announcements of individual stocks: Co-authorship paper with Osaka University on Aggressive NK cell leukemia (ANKL), PPMX-T003.
Perseus Proteomics: Announcements of individual stocks regarding the large exercise of the 28th subscription rights (with exercise price adjustment clause) by third-party allocation.
Perseus Proteomics: Announced that the interim report of PPMX-T003 phase I at the 14th Japan International Health Symposium 2024 has been accepted for presentation.
Perseus Proteomics: Announcements of individual stocks: The mid-term report for the clinical trial of PPMX-T003 has been adopted at the 14th JSH International Symposium in 2024.
Perseus Proteomics: Announcements of individual stocks regarding the large exercise of the 28th subscription rights (with exercise price adjustment clause) by third-party allocation.
Perseus Proteomics: The joint research results of PPMX-T004 were announced at the 2024 annual meeting of the European Association for Cancer Research (EACR 2024).
Perseus Proteomics: Announcements of individual stocks: Presentation of PPMX-T004 at the European Association for Cancer Research (EACR) 2024 Congress.
Perseus Proteomics: Notice regarding the monthly exercise status of the 28th Stock Acquisition Rights (with exercise price amendment clause) through third party allotment
PERSEUS PROTEOMICS: Matters relating to business plans and growth potential
PERSEUS PROTEOMICS: Notice Concerning Mass Exercise of the 28th Stock Acquisition Rights (with Exercise Price Amendment Clauses) through Third-Party Allotment
PERSEUS PROTEOMICS: 2023 financial results presentation materials
PERSEUS PROTEOMICS: Announcement of aggressive NK cell leukemia (ANKL) presentation at the EHA*2024 Hybrid Congress
PERSEUS PROTEOMICS: Announcement on aggressive NK cell leukemia (ANKL) at the European Society of Hematology (EHA) 2024
PERSEUS PROTEOMICS: Notice regarding the recording of non-operating income, non-operating expenses, and extraordinary losses
PERSEUS PROTEOMICS: Notice regarding the recording of non-operating income, non-operating expenses, and extraordinary losses
No Data